Michael J. Pennison

Michael J. Pennison

Auto-generated profile, based on publicly available information

Michael J. Pennison

Wake Forest School of Medicine

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2022 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
KAKojo Agyemang
Kojo Agyemang
AJAllan M. Johansen
Allan M. Johansen
GBGrayson W. Barker
Grayson W. Barker
MPMichael J. Pennison
Michael J. Pennison
KSKimberly Sheffield
Kimberly Sheffield
BPBoris Pasche
Boris Pasche
There is growing evidence that germline mutations in certain genes influence cancer susceptibility, tumor evolution, as well as clinical outcomes. Identification of a disease-causing genetic variant enables testing and diagnosis of at-risk individuals. For breast cancer, several genes such as BRCA1, BRCA2, PALB2, ATM, and CHEK2 act as high- to moderate-penetrance cancer susceptibility genes. Genotyping of these genes informs genetic risk assessment and counseling, as well as treatment and management decisions in the case of high-penetrance genes. TGFBR1*6A (rs11466445) is a common variant of the TGF-β receptor type I (TGFBR1) that has a global minor allelic frequency (MAF) of 0.051 according to the 1000 Genomes Project Consortium. It is emerging as a high frequency, low penetrance tumor susceptibility allele associated with increased cancer risk among several cancer types. The TGFBR1*6A allele has been associated with increased breast cancer risk in women, OR 1.15 (95% CI 1.01–1.31). Functionally, TGFBR1*6A promotes breast cancer cell proliferation, migration, and invasion through the regulation of the ERK pathway and Rho-GTP activation. This review discusses current findings on the genetic, functional, and mechanistic associations between TGFBR1*6A and breast cancer risk and proposes future directions as it relates to genetic association studies and mechanisms of action for tumor growth, metastasis, and immune suppression.

26 June 2023 in Research Square
Verified
Preprint
Open access
PDF file
KAKojo Agyemang
Kojo Agyemang
AJAllan Johansen
Allan Johansen
GBGrayson Barker
Grayson Barker
MPMichael Pennison
Michael Pennison
HJHugo Jimenez
Hugo Jimenez
BPBoris Pasche
Boris Pasche
TGFBR1*6A (rs1466445) is a common low penetrance tumor susceptibility allele with a minor allelic frequency of 0.051. Several meta-analyses show that TGFBR1*6A is associated with breast cancer risk with an OR ranging from 1.15 to 1.30. We developed a novel knockin mouse model of TGFBR1*6A to study mammary cancer development and progression in MMTVneu mice. Here we show that TGFBR1*6A accelerates tumor onset, increases the percentage of mice with tumors, and the percentage of mice with multiple tumors. Age at tumor onset, tumor formation, and tumor multiplicity depend on TGFBR1*6A allelic dosage. Functional characterization shows that TGFBR1*6A confers higher tumor growth and clonogenicity and enhances G0/G1 cell cycle progression through downregulation of p27. These findings establish TGFBR1*6A as a potent modifier of breast cancer development and progression, which may affect more than 10% of patients with breast cancer.